INTRODUCTION

Cardiovascular disease remains the leading cause of disability and death and causes a tremendous social and financial burden worldwide. Coronary artery disease (CAD) is the most common type of cardiovascular disease and accounts for more than half of all cardiovascular events in patients over 75 years old. CAD turns to be the second leading cause of death in China.

The association between IL-17A and IL-23R polymorphisms and coronary artery disease risk in a Middle Eastern Chinese population

Qiang Zhao¹,² | Huaxin Jiang³ | Teng Ma² | Hao Qiu² | Ming Guo² | Xinghua Zhang¹

¹Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
²Department of Cardiology, Affiliated Tengzhou Central People's Hospital of Jining Medical University, Jining Medical University, Tengzhou, China
³Department of Clinical Laboratory, Affiliated Tengzhou Central People's Hospital of Jining Medical University, Jining Medical University, Tengzhou, China

Correspondence
Xinghua Zhang, Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Email: xhzhang213@163.com

Background: Polymorphisms in IL-17A and IL-23R may affect the expression of these genes and could contribute to a patient's susceptibility to coronary artery disease (CAD). Although this association was investigated by previous studies, the relationship remains unclear.

Method: We conducted this hospital-based case-control study to determine whether polymorphisms in these two genes could be associated with a risk of CAD. A total of 191 patients and 131 controls, as determined by SXscore, were enrolled in this study. The genotyping was performed with the Sequenom MassARRAY platform.

Results: The results showed that the FPG and HbA1C levels were higher in patients with CAD than in the controls. In addition, the HDL and ApoA1 levels were significantly higher in the controls than in the cases. In contrast, the Lp(a) level was significantly lower in the controls than in the patients. The IL-17A rs2275913 and IL-23R rs6682925 polymorphisms were associated with an increased risk of CAD (rs2275913: AA vs GG: crude OR = 2.16, 95% CI = 1.08-4.30; AG/AA vs GG: crude OR = 1.81, 95% CI = 1.04-3.15; rs6682925 CC vs TT: crude OR = 1.91, 95% CI = 1.00-3.63). The subgroup analysis by SXscore revealed that the IL-23R rs6682925 polymorphism (CT/CC vs TT: crude OR = 3.72, 95% CI = 1.19-11.66) was associated with an increased risk of CAD in patients with a high SXscore.

Conclusion: This study suggested that T2DM, Lp(a), HDL-c, and ApoA1 were risk factors of CAD and that the IL-17A rs2275913 and IL-23R rs6682925 polymorphisms may contribute to susceptibility to CAD.

KEYWORDS
CAD, IL-17A, IL-23R, polymorphism, susceptibility

1 INTRODUCTION

Cardiovascular disease remains the leading cause of disability and death and causes a tremendous social and financial burden worldwide. Coronary artery disease (CAD) is the most common type of cardiovascular disease and accounts for more than half of all cardiovascular events in patients over 75 years old. CAD turns to be the second leading cause of death in China.
Although the precise mechanisms remain unclear, epidemiology studies have suggested that CAD is the result of an interaction between environmental and genetic factors. Several risk factors, such as chronic diseases (hypertension, hypercholesterolemia, diabetes mellitus, etc), smoking, age, and gender are responsible for the occurrence of CAD. In contrast, genome-wide analysis (GWAS) studies that were based on large sample sizes also deduced that genetic factors contributed to approximately 40%-50% of the risk of CAD and were also supported by family- or twin-based epidemiological studies.12

Previous studies have reported that inflammation is involved in the pathogenesis of CAD by producing oxidative damage,7 promoting cellular proliferation, and affecting plaque evolution and destabilization8; thus, the presence of proinflammatory cytokines is considered to be a risk factor for CAD.

The proinflammatory cytokine IL-17 has six isoforms (IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F),9 and IL-17A and IL-17F have been found to play role in the formation of plaque lesions during atherogenesis.10,11 IL-17A and IL-17F contribute to the T cell–mediated immune response by forming a heterodimer that binds to a receptor to stimulate downstream signaling pathways.12 In addition, genetic variations in IL-17 have been suggested to be risk factors of CAD; however, this conclusion is not always consistent,13 and this inconsistency may be attributed to differences in sample size, the characteristics of the enrolled participants, and ethnicities. The proinflammatory cytokine IL-23 has been implicated in atherogenesis.14,15 Additionally, IL-23 receptor (IL-23R) is composed of the IL-23R subunit and the IL-12Rβ1 subunit, which together form the IL-23 receptor complex, and both IL-23 and IL-23R are required for IL-23 signaling, which is essential for the Th17 cell–mediated immune response. Moreover, the IL-23/IL-17 axis has been identified as an important inflammation pathway that plays a vital role in inflammatory and autoimmune diseases. Molecular epidemiological studies have reported that genetic variations in IL-23 contribute to the susceptibility of CAD.16 However, whether genetic variations in the genes of the IL-23/IL-17 axis are associated with an increased risk of CAD is largely unknown, especially in the Chinese Han population. To evaluate the contribution of genetic variations in IL-17A, IL-17F, and IL-23 to the risk of CAD, we conducted this hospital-based case-control study.

2.2 | Coronary angiography and SXscore

A coronary angiography was performed according to the method of Judkins, and CAD was defined as the presence of a luminal diameter stenosis of ≥50% in the left main coronary artery, left anterior descending artery or its first diagonal branch, left circumflex artery or its first obtuse marginal branch, and right coronary artery. The control subjects were those who showed <30% stenosis in all major vessels. Two experienced cardiologists performed the coronary angiography on every participant and analyzed the images separately. According to baseline diagnostic angiogram, each coronary lesion that created a stenosis obstructing ≥50% of the diameter in vessels ≥1.5 mm was scored separately, and these scores were added to produce the overall SXscore, which was calculated using the SXscore algorithm. This algorithm is available on the SYNTAX website. The patients’ SXscores were independently assessed by two experienced interventional cardiologists who were blinded to the carotid-US data. These cardiologists had previously calculated SXscore.

2.3 | Laboratory measurements

Blood samples of all subjects were obtained in the morning after a 10-hour overnight fast. The serum levels of FPG, serum creatinine (Scr), serum uric acid (sUA), cysteine (Cys), blood urea and nitrogen (BUN), and the lipid profiles, which included the triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), lipoprotein(a) (Lp(a)), apolipoprotein A1 (ApoA1), and apolipoprotein B (ApoB) levels, were quantified by enzymatic colorimetry methods on a Cobas 8000 autoanalyzer (Roche, Mannheim, Germany). HbA1c was detected by high-performance liquid chromatography (Tosoh Automated Glycohemoglobin Analyzer, TOSOH, Japan).
2.4 | Genotyping of polymorphisms

To identify the gene polymorphisms that are involved in the IL-23/IL-17 axis, we retrieved the information of potential related polymorphisms from the National Center for Biotechnology Information dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP) and screened the published studies to obtain the potential risk polymorphism; then, the potential polymorphisms that met the following criteria were enrolled: (a) published results reported to be associated with an increased risk of CAD or a related disease; (b) the minor allele frequency (MAF) is not <5% in the Han Chinese population; and (c) located in the exons, promoter region, 5′ untranslated regions (UTR) or 3′ UTR.

The whole blood of all participants was collected in a vacutainer containing EDTA for the genotyping procedure. The genomic DNA was isolated based on a GoldMag-Mini Whole Blood Genomic DNA Purification kit (GoldMag Co. Ltd., Xian, China). The genotyping was performed on the Sequenom MassARRAY® system (iPLEX GOLD; Sequenom, San Diego, CA) according to the manufacturer’s recommendations. Briefly, the DNA purity was measured by spectrometry (DU530UV/VIS spectrophotometer; Beckman Instruments, Fullerton, CA), and then, the PCR was performed with extension primers. The reaction products were dispensed onto a SpectroCHIP bioarray (Sequenom, San Diego, CA) and assayed on the MassARRAY platform. Mass differences were detected with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). The MassARRAY Workstation v.3.3 software was used to process and analyze the iPLEX SpectroCHIP bioarray, while the Typer Analyzer v.3.4 software was used to analyze all of the genotypes that were obtained from the assays.

2.5 | Statistical analysis

The ANCOVA test was used to compare the differences in biochemical parameters among groups. For the case-control study, the statistical analysis for genotype distribution was performed by the chi-square test with SPSS 13.0 for Windows (SPSS, Chicago, IL). The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a logistic regression model that was adjusted for covariates, including age, sex, BMI, smoking and alcohol consumption, history of hypertension and T2DM, and HDL-C, LDL-C, TG, and TC levels. A P value < 0.05 was considered to represent a statistically significant difference.

3 | RESULTS

3.1 | General characteristics

A total of 322 patients were enrolled in this study, and 131 patients with an SXscore of 0 were identified as controls. A total of 191 patients were divided into the Low SXscore (≤22) (n = 151) and High SXscore (>22) (n = 40) subgroups. There was no significant difference among the cases and controls for BMI, age, and prevalence of hypertension and alcohol consumption (P all > 0.05). However, there was a significant difference between groups for gender (P = 0.023), prevalence of smokers (P = 0.001), and patients with T2DM (P < 0.001), as shown in Table 1.

| Characteristics | Control | CAD | P-value |
|-----------------|---------|-----|---------|
| Gender, male/female, % | 48.85/51.15 | 61.78/38.22 | 0.023 |
| Age, y | 59.30 ± 7.76 | 60.82 ± 8.96 | 0.116 |
| Body mass index, kg/m² | 25.66 ± 3.55 | 25.58 ± 3.48 | 0.840 |
| Current or former smoker, % | 28.24 | 47.12 | 0.001 |
| Alcohol consumption | 24.43 | 25.65 | 0.682 |
| Hypertension, % | 38.17 | 49.74 | 0.052 |
| Type 2 diabetes mellitus, % | 18.32 | 41.88 | 0.000 |
| Fasting plasma glucose, mmol/L | 5.84 ± 1.96 | 6.54 ± 2.37 | 0.006 |
| Blood hemoglobin A1c, % | 5.96 ± 1.06 | 6.67 ± 1.46 | 0.000 |
| TG | 1.60 ± 1.21 | 1.58 ± 0.94 | 0.882 |
| Serum triglycerides, mmol/L | 4.39 ± 0.95 | 4.33 ± 1.18 | 0.600 |
| Serum HDL cholesterol, mmol/L | 1.31 ± 0.36 | 1.15 ± 0.34 | 0.000 |
| Serum LDL cholesterol, mmol/L | 2.91 ± 0.87 | 2.74 ± 0.96 | 0.127 |
| Lp(a) | 42.51 ± 71.35 | 60.34 ± 66.93 | 0.023 |
| ApoA1 | 1.27 ± 0.20 | 1.20 ± 0.26 | 0.017 |
| ApoB | 0.94 ± 0.24 | 0.97 ± 0.36 | 0.343 |
| Blood urea nitrogen (BUN) | 5.13 ± 1.49 | 5.35 ± 1.81 | 0.237 |
| Serum creatinine (Scr), µmol/L | 68.80 ± 16.97 | 72.87 ± 28.48 | 0.144 |
| Serum uric acid, µmol/L | 282.77 ± 76.53 | 295.23 ± 80.56 | 0.165 |
| Cys | 11.49 ± 4.85 | 12.77 ± 7.00 | 0.070 |
3.2 | Clinical characteristics

For the serum indexes, no significant differences were found for the levels of BUN, Scr, sUA, or Cys (P_all > 0.05) between the groups. However, the levels of FPG (CAD: 6.54 ± 2.37 vs controls: 5.84 ± 1.96, P = 0.006) and HbA1C (CAD: 6.67 ± 1.46 vs controls: 5.96 ± 1.06, P = 0.006) were higher in patients with CAD than in controls, as shown in Table 1. For the lipid profile, the levels of HDL (1.31 ± 0.36 vs 1.15 ± 0.34, P < 0.001) and ApoA1 (1.27 ± 0.20 vs 1.20 ± 0.26, P = 0.017) were significantly higher in the controls than those in cases, as shown in Table 1. In contrast, the level of Lp(a) in the cases was significantly higher than that of controls (42.51 ± 71.35 vs 60.34 ± 66.93), as shown in Table 1. In addition, there were no significant differences among groups for the TG, TC, LDL, and ApoB levels, as shown in Table 1.

3.3 | Association between polymorphisms and CAD risk

The genotype frequencies of the selected polymorphisms in the controls did not deviate from HWE (shown in Table S1). Seven polymorphisms in IL-17A/F and IL-23R were observed in this study, and the logistic regression analysis revealed that IL-17A rs2275913 was associated with an increased risk of CAD (AA vs GG: crude OR = 2.16, 95% CI = 1.08-4.30; AG/AA vs GG: crude OR = 1.81, 95% CI = 1.04-3.15). Similarly, the IL-23R rs6682925 polymorphism

| Gene  | SNP  | Genotype | Cases, n (%) | Controls, n (%) | OR (95% CI) | OR (95% CI)* |
|-------|------|----------|--------------|----------------|-------------|-------------|
| IL17A | rs8193036 | CC       | 107 (56.02)  | 75 (57.25)     | Reference   | Reference   |
|       |       | CT       | 73 (38.22)   | 73 (32.82)     | 1.19 (0.74, 1.92) | 1.22 (0.72, 2.05) |
|       |       | TT       | 11 (5.46)    | 13 (9.22)      | 0.59 (0.25, 1.40) | 0.63 (0.25, 1.62) |
|       |       | CT/TT    | 84 (43.98)   | 56 (42.75)     | 1.05 (0.67, 1.65) | 1.11 (0.69, 1.81) |
| rs2275913 | GG    | 30 (15.71) | 33 (25.19)   | Reference     | Reference   |
| AG    | 112 (58.64) | 73 (55.73) | 1.69 (0.95, 3.00) | 1.45 (0.78, 2.67) |
| AA    | 49 (25.65)   | 25 (19.08)  | 2.16 (1.08, 4.30)* | 2.21 (0.95, 5.19) |
|       | 161 (84.29)  | 98 (74.81)  | 1.81 (1.04, 3.15)* | 1.62 (0.89, 2.93) |
| rs3748067 | CC    | 141 (73.82) | 94 (71.76)   | Reference     | Reference   |
| CT    | 48 (25.13)   | 33 (25.19)  | 0.97 (0.58, 1.62) | 1.03 (0.59, 1.78) |
| TT    | 2 (1.05)     | 4 (3.05)    | 0.33 (0.06, 1.86) | 0.36 (0.06, 2.16) |
| CT/TT | 50 (26.18)   | 37 (28.24)  | 0.90 (0.55, 1.48) | 0.95 (0.55, 1.62) |
| IL17F | rs763780 | TT       | 155 (81.15)  | 109 (83.21)    | Reference   | Reference   |
|       |       | CT       | 34 (17.80)   | 20 (15.27)     | 1.20 (0.65, 2.19) | 1.17 (0.61, 2.25) |
|       |       | GG       | 2 (1.05)     | 2 (1.53)       | 0.70 (0.10, 5.07) | 0.39 (0.04, 3.54) |
|       |       | GT/GG    | 36 (18.85)   | 22 (16.79)     | 1.15 (0.64, 2.06) | 1.09 (0.57, 2.06) |
| IL23R | rs6682925  | TT       | 52 (27.32)   | 42 (32.06)     | Reference   | Reference   |
|       |       | CT       | 87 (45.55)   | 67 (51.15)     | 1.05 (0.63, 1.76) | 1.05 (0.60, 1.85) |
|       |       | CC       | 52 (27.23)   | 22 (16.79)     | 1.91 (1.00, 3.63)* | 1.94 (0.95, 3.93) |
|       |       | CT/CC    | 139 (72.77)  | 89 (67.94)     | 1.26 (0.78, 2.05) | 1.25 (0.74, 2.12) |
| rs1884444 | TT    | 69 (36.13) | 47 (35.88)   | Reference     | Reference   |
|       |       | CT       | 92 (48.17)   | 67 (51.15)     | 0.94 (0.58, 1.52) | 1.11 (0.65, 1.89) |
|       |       | GG       | 30 (15.71)   | 17 (12.98)     | 1.20 (0.60, 2.42) | 1.37 (0.63, 2.97) |
|       |       | GT/CC    | 122 (63.87)  | 84 (64.12)     | 0.99 (0.62, 1.57) | 1.13 (0.68, 1.87) |
| rs10889677 | GG   | 93 (48.69) | 70 (53.44)   | Reference     | Reference   |
|       |       | GA       | 85 (44.50)   | 50 (38.17)     | 1.28 (0.80, 2.04) | 1.38 (0.83, 2.28) |
|       |       | AA       | 13 (6.81)    | 11 (8.40)      | 0.89 (0.38, 2.10) | 0.75 (0.28, 2.00) |
|       |       | GA/AA    | 98 (51.31)   | 61 (46.56)     | 1.21 (0.78, 1.89) | 1.24 (0.77, 2.01) |

OR, odds ratio.

*Adjusted for age, gender, smoking, drinking, hypertension, and type 2 diabetes mellitus.

**P = 0.028,

*p = 0.035,

*P = 0.048
was observed to be associated with an increased risk of CAD (CC vs TT: crude OR = 1.91, 95% CI = 1.00-3.63). However, all of these significant associations were not maintained in the adjusted model, as shown in Table 2.

In addition, the logistic regression analysis showed that I L‐17A rs8193036 and rs3748067, I L‐17F rs763780, and I L23R rs1884444 and rs10889677 were not associated with CAD risk.

### 3.4 Subgroup analysis of polymorphisms and CAD risk

The subgroup analysis was conducted based on the SXscore (low SXscore ≤ 22 and high SXscore > 22). The logistic regression analysis revealed that IL‐23R rs6682925 (CT/CC vs TT: crude OR = 3.72, 95% CI = 1.19-11.66) and rs10889677 (CA/CC vs AA: crude OR = 2.38, 95% CI = 1.03-5.50) were associated with an increased risk in patients with a high SXscore, as shown in Table 3.

### 4 DISCUSSION

It is well-known that T2DM is a risk of CAD, and the published data show that CAD affects approximately 32.2% of all people with T2DM globally,17 which is consistent with our results showing that the prevalence of T2DM in patients was higher than that in controls and that the levels of FPG and HbA1C were higher in patients than in controls. Lp(a) has been identified as a risk factor for CAD, and elevated Lp(a) levels were suggested to be independently associated with the presence and severity of CAD in patients with T2DM.18 In this study, we observed that the level of Lp(a) in patients was higher than that in controls. In contrast, the levels of the protective factors HDL‐c and ApoA1 were higher in the controls than in the patients.

The I L‐17A rs2275913 polymorphism is a substitution of the G by an A nucleotide base in the promoter region, and it has been suggested to be associated with several diseases, including CAD; however, this association may be inconsistent, as a published meta‐analysis showed that rs2275913 was not associated with risk of CAD.13 In this study, we observed the rs2275913 AA and AG/AA genotype to be associated with an increased risk of CAD, which was consistent with the results of previous studies.20 In contrast, the significant association could not be maintained after the analysis was adjusted for the demographic characteristics of participants, indicating that the association between rs2275913 and CAD risk could be modified by patient characteristics. A functional study found that the rs2275913 A allele is associated with a higher promoter activity of I L‐17A, suggesting that the rs2275913 AA genotype appears to contribute to greater levels of inflammation, which can lead to several diseases, including CAD; this finding was consistent with the previous results showing that IL‐17 may contribute to the severity of CAD.21

#### TABLE 3 Subgroup analysis of the associations between polymorphisms and CAD risk

| Gene   | SNP       | Genotype | Low SXscore (≤22) | High SXscore (>22) |
|--------|-----------|----------|-------------------|-------------------|
|        |           |          | Cases/Controls OR (95% CI)a | Cases/Controls OR (95% CI)a |
| IL17A  | rs8193036 | CC       | 87/75 Reference | 20/75 Reference |
|        |           | CT/TT    | 64/56 1.05 (0.63, 1.75) | 20/56 1.36 (0.62, 2.98) |
|        | rs2275913 | GG       | 26/33 Reference | 4/33 Reference |
|        |           | AG/AA    | 125/98 1.42 (0.77, 2.64) | 36/98 2.77 (0.83, 9.19) |
|        | rs3748067 | CC       | 112/94 Reference | 29/94 Reference |
|        |           | CT/TT    | 39/37 0.97 (0.55, 1.70) | 11/37 0.87 (0.36, 2.14) |
| IL17F  | rs763780  | TT       | 120/109 Reference | 35/109 Reference |
|        |           | GT/GG    | 31/22 1.27 (0.66, 2.46) | 0.45 (0.14, 1.47) |
| IL23R  | rs6682925 | TT       | 47/42 Reference | 5/42 Reference |
|        |           | CT/CC    | 104/89 1.03 (0.60, 1.74) | 35/89 3.72 (1.19, 11.66)* |
|        | rs1884444 | TT       | 59/47 Reference | 10/47 Reference |
|        |           | GT/GG    | 92/84 0.98 (0.58, 1.65) | 30/84 2.23 (0.87, 5.71) |
|        | rs10889677| AA       | 80/70 Reference | 13/70 Reference |
|        |           | CA/CC    | 71/61 1.07 (0.65, 1.77) | 27/61 2.38 (1.03, 5.50)§ |

OR, odds ratio.

aAdjusted for age, gender, smoking, drinking, and hypertension, and type 2 diabetes mellitus.

* P = 0.015,

§ P = 0.02.
the promoter activity of IL-23R. In addition, IL-23/IL-23R polymorphisms are involved in pathogenesis of CAD by regulating the immune system. A previous study showed that the IL-23/IL-17 inflammatory signal could adjust the balance of Th17/Treg cells, a process which was related to the progression of CAD. Moreover, the IL-23 level was suggested to be a marker of patients with CAD.

This study attempted to investigate the contributions of the IL-17A and IL-23R polymorphisms to CAD susceptibility. Although polymorphisms in IL-17A or IL-23R were shown by several previous studies to be associated with the risk of CAD, to our knowledge, this is the first study that attempted to investigate the polymorphisms in the genes that are involved in the IL-23/IL-17 axis in an attempt to illustrate the systemic genetic risk of CAD. To confirm the lack of CAD in the individuals of the control group, we enrolled patients who had an SXScore of 0 as controls, which was in accordance with the purpose of this study. In addition, we reported all of the results of this study, which may be discussed in further studies. However, there were some limitations, which will be described. First, the sample size of this study was relatively small, and this may limit the statistical power, especially for the subgroup analysis. Second, CAD is a chronic disease; several environmental factors are involved in the pathology of disease progression, so the results of this study may be affected by limited characteristics of the enrolled subjects. Third, we failed to investigate the association between genotypes and gene expression.

In short, this study suggested that T2DM, Lp(a), HDL-c, and ApoA1 were risk factors of CAD, and the IL-17A rs2275913 and IL-23R rs6682925 polymorphisms may contribute to the susceptibility of CAD, which should be confirmed by further studies with large sample sizes.

CONFLICT OF INTERESTS

The authors have declared that no competing interest exists.

ORCID

Xinghua Zhang https://orcid.org/0000-0003-3660-305X

REFERENCES

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):1177-1220.
2. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29-e322.
3. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67-e492.
4. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1499-1544.
5. Zdravkovic S, Wienke A, Pedersen NL, Marenberg ME, Yashin AI, De Faire U. Heritability of death from coronary heart disease: a 36-year follow-up of 20,966 Swedish twins. J Intern Med. 2002;252(3):247-254.
6. Williams RR, Hunt SC, Heiss G, et al. Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). Am J Cardiol. 2001;87(2):129-135.
7. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995;91(9):2488-2496.
8. Mauriello A, Sangiorgi G, Fratoni S, et al. Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction. J Am Coll Cardiol. 2005;45(10):1585-1593.
9. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9(8):556-567.
10. de Boer OJ, van der Meer JJ, Teeling P, et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol. 2010;220(4):499-508.
11. Erbel C, Dengler TJ, Wanger S, et al. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res Cardiol. 2011;106(1):125-134.
12. Wright JF, Guo Y, Quazi A, et al. Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem. 2007;282(18):13447-13455.
13. Bao MH, Luo HQ, Xiang J, et al. Meta-analysis for the association between polymorphisms in interleukin-17A and risk of coronary artery disease. Int J Environ Res Public Health. 2016;13(7):660.
14. Ma S, Zhong D, Chen H, et al. The immunomodulatory effect of bone marrow stromal cells (BMSCs) on interleukin (IL)-23/IL-17-mediated ischemic stroke in mice. J Neuroimmun. 2013;257(1-2):28-35.
15. David A, Saitta S, De Caridi G, et al. Different serum levels of interleukin-23 in patients affected by peripheral arterial disease. Vascular. 2014;22(6):471-472.
16. Kave M, Shadman M, Alizadeh A, Samadi M. Analysis of the association between IL-23R rs11209026 polymorphism and incidence of atherosclerosis. Int J Immunogenet. 2015;42(5):341-345.
17. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17(1):83.
18. Zhang H-W, Zhao X, Guo Y-L, et al. Elevated lipoprotein (a) levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2018;28(10):980-986.
19. Shuang L, Li Z, Chen F, et al. Association between interleukin-17 gene polymorphisms and risk of coronary artery disease. Int J Clin Exp Pathol. 2015;8(9):11653-11658.
20. Geng GY, Liu HL, Zhao YJ, Wu L, Mao L, Ba N. Correlation between polymorphisms in the IL-17A and IL-17F genes and development of coronary artery disease. Genet Mol Res. 2015;14(3):11488-11494.
21. Min X, Lu M, Tu S, et al. Serum cytokine profile in relation to the severity of coronary artery disease. Biomed Res Int. 2017;2017:4013685.
22. Zhang M, Cai Z-R, Zhang B, et al. Functional polymorphisms in interleukin-23 receptor and susceptibility to coronary artery disease. J Investigative Medicine. 2014;63(12):891-897.
23. Xu Y, Liu Y, Pan S, et al. IL-23R polymorphisms, HBV infection, and risk of hepatocellular carcinoma in a high-risk Chinese population. J Gastroenterol. 2013;48(1):125-131.
24. Khojasteh-Fard M, Abolhajal M, Amirip A, et al. IL-23 gene expression in PBMCs of patients with coronary artery disease. Dis Markers. 2012;33(6):289-293.
25. Li Q, Shan Q, Sang X, Zhu R, Chen X, Cao G. Total glycosides of peony protects against inflammatory bowel disease by regulating IL-23/IL-17 axis and Th17/Treg balance. *Am J Chin Med*. 2019;47:177-201.

26. Potekhina AV, Pylaeva E, Provatorov S, et al. Treg/Th17 balance in stable CAD patients with different stages of coronary atherosclerosis. *Atherosclerosis*. 2015;238(1):17-21.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Zhao Q, Jiang H, Ma T, Qiu H, Guo M, Zhang X. The association between *IL-17A* and *IL-23R* polymorphisms and coronary artery disease risk in a Middle Eastern Chinese population. *J Clin Lab Anal*. 2019;33:e22893. [https://doi.org/10.1002/jcla.22893](https://doi.org/10.1002/jcla.22893)